Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Medical Genetics

Genetics and Predicting Outcomes in Neurogenic AMC

At a Glance

Neurogenic Arthrogryposis Multiplex Congenita (AMC) is caused by various genetic mutations that determine a child's prognosis. Identifying the specific gene helps classify the condition as isolated (affecting only joints and muscles) or syndromic (affecting the brain and other systems).

Neurogenic Arthrogryposis Multiplex Congenita (AMC) is a “broad tent” that includes many different genetic causes. While the physical symptom—stiff joints at birth—may look similar across different people, the underlying genetic “blueprint” determines much of the long-term outlook [1][2].

Decoding the Genetics

Because Neurogenic AMC is highly heterogeneous (meaning it can be caused by many different gene changes), identifying the specific variant is critical for predicting outcomes [1][3].

  • ZC4H2 (Wieacker-Wolff Syndrome): Often leads to a syndromic presentation. This can involve global developmental delay, unique facial features, and “jaw-winking” (Marcus Gunn phenomenon) [4][5].
  • CNTNAP1: This is associated with a more severe, often progressive phenotype. It can involve neurodegeneration (breakdown of nerve cells over time), significant brain and cerebellar atrophy (shrinking), and severe weakness [6][7].
  • SCN4A / RYR1: Mutations in these genes are strongly linked to fetal akinesia and congenital contractures affecting how muscles and nerves interact during prenatal development [8].
  • SCYL2 (AMC4): A rare variant that can involve severe joint stiffness, epilepsy, and brain malformations like corpus callosum agenesis (missing the bridge between the two halves of the brain) [9][10].

“Isolated” vs. “Syndromic” AMC

Doctors often categorize AMC into two groups to help families understand what to expect:

  1. Isolated Musculoskeletal Phenotype: The condition primarily affects the joints and muscles. These individuals often have typical intelligence and hit cognitive milestones normally [11].
  2. Syndromic Phenotype: The genetic change affects multiple systems. In addition to joint stiffness, this presentation may involve microcephaly (smaller head size), epilepsy (seizures), or significant developmental delays [12][13][14].

Respiratory and Bulbar Risks

In severe neurogenic forms, the same “wiring” issues that affect the limbs can also affect the muscles used for breathing and swallowing (bulbar muscles) [15][16].

  • Pulmonary Hypoplasia: If a baby cannot move their chest wall effectively in the womb, their lungs may not fully expand and grow (underdeveloped lungs). This is a major factor in the health and survival of newborns with severe AMC [16][1].
  • Swallowing Complications: Weakness in the throat muscles can lead to difficulty feeding and a risk of “silent” aspiration, where food or liquid enters the lungs without coughing [15].

Predicting Mobility: Standardized Motor Scales

To track progress and set realistic expectations, specialists use standardized motor function scales (such as the GMFC-AMC or similar functional classification tools) [17]. These scales assess current mobility to:

  • Standardize Tracking: Help the care team communicate clearly about whether walking independently, using a walker, or requiring a wheelchair is the most likely outcome [17][18].
  • Set Benchmarks: Monitor how interventions—like bracing or surgery—are affecting functional levels over time [18][19].

Facing Uncertainty

While genetics provide a roadmap, they do not tell the whole story. Every journey is unique, and prognostic uncertainty is a common part of the experience [1]. Multidisciplinary care—combining neurology, genetics, and therapy—is the best way to support individual paths as they unfold [20][21].

Common questions in this guide

Why is genetic testing important for neurogenic AMC?
Because neurogenic AMC can be caused by many different gene changes, identifying the specific genetic variant helps doctors predict long-term outcomes. It provides a crucial roadmap for anticipating your child's physical and cognitive development.
What is the difference between isolated and syndromic AMC?
Isolated AMC primarily affects the joints and muscles, and children often reach cognitive milestones normally. Syndromic AMC affects multiple body systems and may involve developmental delays, a smaller head size, or seizures.
Can neurogenic AMC affect breathing and swallowing?
Yes, severe forms of neurogenic AMC can affect the muscles used for breathing and swallowing. This can lead to underdeveloped lungs or swallowing difficulties that put a baby at risk for silent aspiration.
How do doctors track my child's mobility with AMC?
Specialists use standardized motor function scales to track your child's mobility over time. These scales help the care team set goals, monitor how well treatments like bracing or surgery are working, and predict future mobility needs.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the genetic results, what is the expected clinical 'roadmap' for cognitive and physical development?
  2. 2.Which level on the standardized motor function scales best describes the current mobility, and how does this affect our long-term goals?
  3. 3.Are there findings on the brain MRI, such as cerebral atrophy, that are associated with a higher risk for epilepsy?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Arthrogryposis Multiplex Congenita.

    Langston S, Chu A

    Pediatric annals 2020; (49(7)):e299-e304 doi:10.3928/19382359-20200624-01.

    PMID: 32674167
  2. 2

    Postnatal Diagnostic Workup in Children With Arthrogryposis: A Series of 82 Patients.

    Chareyre J, Neuraz A, Badina A, et al.

    Journal of child neurology 2021; (36(12)):1071-1077 doi:10.1177/08830738211022972.

    PMID: 34410827
  3. 3

    Collaborating to advance interdisciplinary care for individuals with arthrogryposis.

    Dahan-Oliel N, Hall JG

    American journal of medical genetics. Part C, Seminars in medical genetics 2019; (181(3)):273-276 doi:10.1002/ajmg.c.31741.

    PMID: 31471949
  4. 4

    A 7-year old female with arthrogryposis multiplex congenita, Duane retraction syndrome, and Marcus Gunn phenomenon due to a ZC4H2 gene mutation: a clinical presentation of the Wieacker-Wolff syndrome.

    Godfrey D, Torres A, Heidary G, et al.

    Ophthalmic genetics 2021; (42(5)):612-614 doi:10.1080/13816810.2021.1923040.

    PMID: 33949289
  5. 5

    Deleterious de novo variants of X-linked ZC4H2 in females cause a variable phenotype with neurogenic arthrogryposis multiplex congenita.

    Frints SGM, Hennig F, Colombo R, et al.

    Human mutation 2019; (40(12)):2270-2285 doi:10.1002/humu.23841.

    PMID: 31206972
  6. 6

    Absence of Axoglial Paranodal Junctions in a Child With CNTNAP1 Mutations, Hypomyelination, and Arthrogryposis.

    Conant A, Curiel J, Pizzino A, et al.

    Journal of child neurology 2018; (33(10)):642-650 doi:10.1177/0883073818776157.

    PMID: 29882456
  7. 7

    Identification of a novel CNTNAP1 mutation causing arthrogryposis multiplex congenita with cerebral and cerebellar atrophy.

    Lakhani S, Doan R, Almureikhi M, et al.

    European journal of medical genetics 2017; (60(5)):245-249 doi:10.1016/j.ejmg.2017.02.006.

    PMID: 28254648
  8. 8

    De novo mutations of SCN1A are responsible for arthrogryposis broadening the SCN1A-related phenotypes.

    Jaber D, Gitiaux C, Blesson S, et al.

    Journal of medical genetics 2021; (58(11)):737-742 doi:10.1136/jmedgenet-2020-107166.

    PMID: 32928894
  9. 9

    SCYL2-related autosomal recessive neurodevelopmental disorders: Arthrogryposis multiplex congenita-4 and beyond?

    Malbos M, Vera G, Sheth H, et al.

    Clinical genetics 2024; (106(6)):757-763 doi:10.1111/cge.14608.

    PMID: 39169672
  10. 10

    Recessive mutations in SCYL2 cause a novel syndromic form of arthrogryposis in humans.

    Seidahmed MZ, Al-Kindi A, Alsaif HS, et al.

    Human genetics 2020; (139(4)):513-519 doi:10.1007/s00439-020-02117-7.

    PMID: 31960134
  11. 11

    Long-term outcome for patients with arthrogryposis multiplex congenita.

    Dubousset J, Guillaumat M

    Journal of children's orthopaedics 2015; (9(6)):449-58 doi:10.1007/s11832-015-0692-6.

    PMID: 26499455
  12. 12

    Development of an online registry for adults with arthrogryposis multiplex congenita: A protocol paper.

    Sawatzky B, Dahan-Oliel N, Davison AM, et al.

    American journal of medical genetics. Part C, Seminars in medical genetics 2019; (181(3)):454-460 doi:10.1002/ajmg.c.31706.

    PMID: 31099966
  13. 13

    Gene ontology analysis of arthrogryposis (multiple congenital contractures).

    Kiefer J, Hall JG

    American journal of medical genetics. Part C, Seminars in medical genetics 2019; (181(3)):310-326 doi:10.1002/ajmg.c.31733.

    PMID: 31369690
  14. 14

    Recurrent de novo BICD2 mutation associated with arthrogryposis multiplex congenita and bilateral perisylvian polymicrogyria.

    Ravenscroft G, Di Donato N, Hahn G, et al.

    Neuromuscular disorders : NMD 2016; (26(11)):744-748 doi:10.1016/j.nmd.2016.09.009.

    PMID: 27751653
  15. 15

    Disability in adults with arthrogryposis is severe, partly invisible, and varies by genotype.

    Dai S, Dieterich K, Jaeger M, et al.

    Neurology 2018; (90(18)):e1596-e1604 doi:10.1212/WNL.0000000000005418.

    PMID: 29626181
  16. 16

    Pena-Shokeir syndrome: current management strategies and palliative care.

    Adam S, Coetzee M, Honey EM

    The application of clinical genetics 2018; (11()):111-120 doi:10.2147/TACG.S154643.

    PMID: 30498368
  17. 17

    Gross motor functional classification for arthrogryposis multiplex congenita: protocol for co-development involving public with lived and professional experience.

    Araujo CRS, Hyer L, Sienko SE, et al.

    Research involvement and engagement 2025; (12(1)):19 doi:10.1186/s40900-025-00827-8.

    PMID: 41402879
  18. 18

    Psychometric properties of functional mobility outcome measures in children with arthrogryposis multiplex congenita.

    Zidan A, Snider L, Rampakakis E, et al.

    Developmental medicine and child neurology 2026; (68(6)):832-845 doi:10.1111/dmcn.70036.

    PMID: 41124586
  19. 19

    Factors associated with functional mobility in 256 children with arthrogryposis multiplex congenita: A multicentric cross-sectional study.

    Zidan A, Snider L, Rampakakis E, et al.

    Archives of physical medicine and rehabilitation 2025; doi:10.1016/j.apmr.2025.12.014.

    PMID: 41475428
  20. 20

    A rare case of arthrogryposis multiplex congenita in a 2-year-old boy case report.

    Waseem A, Shah AM, Hussain AA, et al.

    SAGE open medical case reports 2023; (11()):2050313X231200418 doi:10.1177/2050313X231200418.

    PMID: 37771653
  21. 21

    Characterization of a group unrelated patients with arthrogryposis multiplex congenita.

    Valdés-Flores M, Casas-Avila L, Hernández-Zamora E, et al.

    Jornal de pediatria 2016; (92(1)):58-64.

    PMID: 26453511

This page explains the genetics and potential outcomes of Neurogenic AMC for educational purposes. Always consult your pediatric neurologist and geneticist to understand your child's specific prognosis and care plan.

Get notified when new evidence is published on Neurogenic arthrogryposis multiplex congenita.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.